



### Patrick J. O'Malley

Partner

patrick.omalley@dlapiper.com

#### San Diego (Golden Triangle)

T: +1 858 677 1471

F: +1 858 638 5071

Patrick O'Malley focuses his practice on general corporate representation of established and emerging life sciences, biotech, medical device and technology companies.

He regularly represents public companies in SEC periodic and current reporting, proxy statements, and related corporate and disclosure advice as well as in capital markets transactions. Patrick also advises numerous private companies in venture capital financing and corporate governance and Board of Director matters. He has also represented both selling companies and acquirers in merger and acquisition transactions.

#### RELATED SERVICES

- Corporate

#### EXPERIENCE

---

#### REPRESENTATIVE MATTERS

- Zeltiq Aesthetics (Nasdaq: ZLTQ) in its US\$105 million initial public offering
- Neothetics in its US\$65 million initial public offering and its sale to Evofem Biosciences
- Nexvet Biopharma (Nasdaq: NVET) in its US\$40 million initial public offering
- Sientra in its US\$115 million follow-on offering
- Halozyme Therapeutics, Inc. in numerous follow-on offerings
- GenMark Diagnostics (Nasdaq: GNMK) in its initial public offering and numerous follow-on offerings
- Maxwell Technologies in its follow-on offering and convertible note offering
- DragonWave (Nasdaq: DRWI; TSX: DRI) in numerous follow-on offerings
- Cytori Therapeutics (Nasdaq: CYTX) in numerous follow-on offerings and rights offering
- Mast Therapeutics, Inc. in its sale to Savara and in numerous follow-on offerings
- QUALCOMM Incorporated in numerous acquisitions, venture financings and other strategic transactions
- DTS in its US\$1.0 billion sale to Tessera Technologies, as well as numerous acquisitions
- NuVasive in its US\$650 million 2.25% Convertible Senior Note offering and numerous acquisitions
- P.F. Chang's China Bistro in its US\$1.1 billion sale to Centerbridge Partners

- The Active Network, Inc. in its US\$1.05 billion sale to Vista Equity Partners
- Life Technologies Corporation in various acquisitions, venture financings and other strategic transactions
- Reva Medical (ASX: RVA) in its convertible note offerings
- aTyr Pharma Inc. in its venture financings and other strategic transactions
- Epic Sciences, Inc. in its venture financings and other strategic transactions

## CREDENTIALS

---

### Admissions

- California

### Prior Experience

- Judicial Extern to Honorable Marilyn Huff, Southern District of California

### Education

- J.D., Georgetown University Law Center 2010  
Member, *The Tax Lawyer*
- B.A., University of Notre Dame 2007

## INSIGHTS

---

### Publications

#### SEC streamlines and modernizes financial disclosure

1 December 2020

A detailed summary of the final rules.

---

#### California legislation and recent stockholder derivative suits push for more board diversity

7 October 2020

California's latest diversity law follows a new wave of shareholder derivative actions attacking the lack of racial diversity in corporate leadership.

---

## NEWS

---

#### DLA Piper advises William Blair & Company and RBC Capital Markets as joint book-running managers in OptimizeRx Corporation's US\$75.5 million underwritten public offering

2 March 2021

DLA Piper represented William Blair & Company, LLC and RBC Capital Markets, LLC as joint book-running managers in connection with an underwritten public offering of 1,523,750 shares of common stock of OptimizeRx Corporation at a price to the

---

public of US\$49.50 per share.

---

### **DLA Piper advises ON24 in its US\$428 million IPO**

3 February 2021

DLA Piper represented ON24 Inc. (NYSE: ONTF) in its initial public offering of 8,560,930 shares of common stock at a price to the public of \$50 per share.

---

### **DLA Piper advises Histogen in its US\$14 million upsized public offering**

6 January 2021

DLA Piper advised Histogen, Inc., in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of US\$1.00 per share.

---

### **DLA Piper acted for Charlotte's Web in its acquisition of Abacus Health**

11 JUN 2020

On June 11, 2020, Charlotte's Web Holdings, Inc. and Abacus Health Products, Inc. announced the completion of their previously-announced arrangement. Under the terms of the Arrangement, Charlotte's Web acquired all of the issued and outstanding shares of Abacus. DLA Piper was pleased to have acted for Charlotte's Web on this transaction.

---

### **DLA Piper announces partnership promotions for 2020**

30 April 2020

DLA Piper is proud to announce that 67 lawyers have been promoted to its partnership. The promotions are effective as of April 1, 2020 in the United States and May 1, 2020 for EMEA and Asia Pacific. The promotions have been made across many of the firm's practice areas in 35 different offices throughout 13 countries.

Across the firm's practices globally, Corporate saw the largest intake of new partners with 19 promotions, followed by Litigation and Regulatory with 15. Intellectual Property and Technology and Finance and Projects had ten and eight promotions respectively, while there were six in Real Estate. Tax and Employment both had four, and there was one in Restructuring.

---